The U.S. Senate passed S.934 – FDA Reauthorization Act of 2017 on Thursday, August 3, 2017, by a 94-1 vote after having been passed by...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
BSUFA II
-
-
H.R.2430 – FDA Reauthorization Act of 2017, a bill reauthorizing all of the U.S. Food and Drug Administration (“FDA”) user fee...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The Biosimilar User Fee Act (“BsUFA”) was originally enacted in 2012, and the current legislative authority is set to expire at the end...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Dr. Leah Christl, the FDA’s Associate Director for Therapeutic Biologics, Office of New Drugs Therapeutic Biologics and Biosimilars Team...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]